European Medicines Agency - Regulatory - Regulation of medicines

D - Description



  Description

Name

c4c-S - conect4children Stichting

Year of foundation 2023 c4c-S has been legally established, however the network has been established and gained experience within a project set up as of 2018
Preterm and/or term newborn Yes
Infants from 1 month to less than 24 months of age Yes
Children from 2 years to less than 12 years of age Yes
Adolescents from 12 years to less than 18 years Yes
Paediatric age ranges of study participants covered by the network 0-18
Multispeciality? Specify we have a network of over 400 experts that cover multiple clinical and methodology paediatric expertise and 20 National Hubs covering over 220 sites for site identification, site feasibility, trial support across Europe as well patient and public involvement experts.
Speciality/disease specific? Specify multispecialty
Conditions covered? Specify paediatrics, rare diseases
Procedure/Intervention specific? Specify expert advice, patient, public involvement and trial support
Number of collaborating countries 30
List of collaborating countries Austria, Belgium, Bulgaria, Cypurs, Chez Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Poland, Portugal, North Macedonia, Romania, Serbia, Spain, Sweden, Switzerland, The Netherlands, Turkey, UK, Ukraine, Uzbekistan
Number of collaborating centres 220
List of collaborating centres Multiple sites through out Europe, 20 National Hubs Contact of National Hub can be found: https://conect4children.org/national-hubs/
Type of activity/studies
Clinical Studies Yes
Experimental research No
Other activity We provide multidisciplinary and multinational insights resulting in high-quality, independent advice reports that can be used in the design of development programs or protocols. Improve patient recruitment and retention through making a study more patient-centric based on the insights of children, young people and families and Set up and conduct paediatric trials faster and more efficiently, thanks to our network of over 220 high-quality sites across 21 countries.